Tag: Novartis

Image accompaying blogpost on "Recap 2021- Indian Patent Case Laws"

Recap 2021- Indian Patent Case Laws

In this post, we bring to you few Patent Cases decided by Indian Courts in the year 2021 Merck Sharp And Dohme Corp & ANR vs YMS Laboratories Private Limited In this case, the plaintiff, owner of patents pertaining to Sitagliptin and its derivative salts, filed an infringement suit against the defendant. The plaintiff prayed for an Ad Interim Injunction during the pendency of the suit. After reviewing the facts presented, the Court granted an Exparte Ad Interim Injunction as the…

Read more

Image for important patent case laws 2021

Important Patent Case law – 2021

In this post, we bring to you Important Patent Cases decided by Indian Courts in year 2021 FMC Corporation & ANR. vs Natco Pharma Limited In this comprehensive judgment with respect to grant of interim injunctions involving a patent relating to “Chlorantraniliprole” (also known as CTPR), the Delhi High Court rejected a valiant effort by the defendant based on several grounds under the patent law. The Court refused to grant permission to the defendant to manufacture and sell the insecticide during…

Read more

Weekly Patent News

Latest Patent & Design Updates – January 2022 – Part 1

In this week's update on patents - India requests emergency meeting of WTO General Council to discuss patent waiver; RGNIIPM announces online advanced training program on patent specification; Taiwan’s revised ‘Accelerated Examination Program’ (AEP) comes into effect from January 01, 2022; USPTO pushes deadline for applications under COVID-19 Prioritized Pilot Program to March 31st, 2022; Novartis announces CAFC ruling on validity of Gilenya patent; Intel can challenge two of Qualcomm's smartphone patents, says U.S. Court of Appeals. India related patent updates…

Read more

The featured image is a quote by John F. Kennedy which reads "There are risks and costs to action. But they are far less than the risks of comfortable inaction"

In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies

During the last two days, two interesting articles addressing accessibility of medical products and methods were published. While one article in 'The Hindu' spoke about capitalism and its inherent hurdles to access, another article written by Professor Arul Scaria in 'The Wire' argued against Niti Aayog's approach towards access to COVID vaccines and medicines. In his article, Professor Scaria specifically pointed out that Government's reluctance to use the compulsory licensing mechanism as a part of the COVID vaccine/medicine access scheme…

Read more

Novartis Case Review

  This Post was first published on 15th May, 2013.   NOVARTIS AG (APPELLANT) Vs. UNION OF INDIA & OTHERS (RESPONDENTS) Decided by the Supreme Court of India, CIVIL APPEAL Nos. 2706-2716 OF 2013.   Brief Facts The Appellant, Novartis, filed an application for patent in 1998 for a crystalline salt form of Imatinib and its use in cancer treatment. It specifically claimed the methanesulfonic acid addition salt form of the compound, Imatinib, called as Imatinib Mesylate (commonly referred to as Glivac or…

Read more

The featured image reads Weekly News Updates: Patent News. The logo of intellepedia also forms part of the featured image. To read more click here.

Voting Machine Patent, Delhi High Court restrains Natco, Samsung and Huawei settle patent dispute and more

  “Indian elections and Patents on voting machines, Delhi High Court restrains Natco from manufacturing cancer drug, Samsung and Huawei end eight - year long patent dispute, Novartis thwarts attempt to invalidate its cancer drug in US and more patent news” presented by the Patent attorneys and experts of BananaIP Counsels, India’s leading Patent Firm. Quote of the Week  “Ideas in your mind have no patent value. They must be expressed or reduced to practice before it is too late” –…

Read more

R.I.P. Professor Karl Jorda, you will be missed

Very few people are truly able to leave an indelible impression on others, not only by the virtue of their work but also by their generosity. One such person is Professor Karl F. Jorda, a name that probably needs no introduction and one whose achievements cannot be summed up in this article alone. Yesterday we received the tragic news that Professor Jorda had passed away at the age of 87. Professor is revered not only by the alumni and faculty…

Read more